Skip to main content Accessibility help
×
Home

STANDARDIZED REPORTING FOR RAPID RELATIVE EFFECTIVENESS ASSESSMENTS OF PHARMACEUTICALS

  • Sarah Kleijnen (a1), Iris Pasternack (a2), Marc Van de Casteele (a3), Bernardette Rossi (a4), Agnese Cangini (a5), Rossella Di Bidino (a6), Marjetka Jelenc (a7), Payam Abrishami (a8), Ilona Autti-Rämö (a9), Hans Seyfried (a10), Ingrid Wildbacher (a10) and Wim G. Goettsch (a11)...

Abstract

Objectives: Many European countries perform rapid assessments of the relative effectiveness (RE) of pharmaceuticals as part of the reimbursement decision making process. Increased sharing of information on RE across countries may save costs and reduce duplication of work. The objective of this article is to describe the development of a tool for rapid assessment of RE of new pharmaceuticals that enter the market, the HTA Core Model® for Rapid Relative Effectiveness Assessment (REA) of Pharmaceuticals.

Methods: Eighteen member organisations of the European Network of Health Technology Assessment (EUnetHTA) participated in the development of the model. Different versions of the model were developed and piloted in this collaboration and adjusted accordingly based on feedback on the content and feasibility of the model.

Results: The final model deviates from the traditional HTA Core Model® used for assessing other types of technologies. This is due to the limited scope (strong focus on RE), the timing of the assessment (just after market authorisation), and strict timelines (e.g. 90 days) required for performing the assessment. The number of domains and assessment elements was limited and it was decided that the primary information sources should preferably be a submission file provided by the marketing authorisation holder and the European Public Assessment Report.

Conclusions: The HTA Core Model® for Rapid REA (version 3.0) was developed to produce standardised transparent RE information of pharmaceuticals. Further piloting can provide input for possible improvements, such as further refining the assessment elements and new methodological guidance on relevant areas.

Copyright

References

Hide All
1. Eichler, HG, Bloechl-Daum, B, Abadie, E, et al. Relative efficacy of drugs: An emerging issue between regulatory agencies and third-party payers. Nat Rev Drug Discov. 2010;9:277291.
2. Franken, M, Nilsson, F, Sandmann, F, de Boer, A, Koopmanschap, M. Unravelling Drug reimbursement outcomes: A comparative study of the role of pharmacoeconomic evidence in Dutch and Swedish reimbursement decision making. Pharmacoeconomics. 2013;31:781797.
3. Kleijnen, S, George, E, Goulden, S, et al. Relative effectiveness assessment of pharmaceuticals: Similarities and differences in 29 jurisdictions. Value Health. 2012;15:954960.
4. Kleijnen, S, Goettsch, W, d’Andon, A, et al. EUnetHTA JA WP5/JA1: Relative Effectiveness Assessment (RE assessment) of pharmaceuticals. Background review. July 2011. http://eunethta.fedimbo.belgium.be/sites/5026.fedimbo.belgium.be/files/Final%20version%20of%20Background%20Review%20on%20Relative%20Effectiveness%20Assessment%2Bappendix.pdf (accessed September 19, 2013).
5. Lampe, K, Mäkelä, M, Garrido, MV, et al. The HTA core model: A novel method for producing and reporting health technology assessments. Int J Technol Assess Health Care. 2009;25 (Suppl 2):920.
6. Pavlovic M, Teljeur C, Wieseler B, Klemp M, Cleemput I, Neyt M. Endpoints for relative effectiveness assessment (REA) of pharmaceuticals. Int J Technol Assess Heath Care. 2014;30:508-513.
7. High Level Pharmaceutical Forum 2005–2008. Conclusions and recommendations. 2008. http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/pharmaforum_final_conclusions_brochure_en.pdf (accessed September 19, 2013).
8. High Level Pharmaceutical Forum. Core principles on relative effectiveness. 2008. http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/rea_principles_en.pdf (accessed September 19, 2013).
9. Kleijnen, S, Pasternack, I, Rannanheimo, P, et al. Piloting international production of rapid relative effectiveness assessments of pharmaceuticals. Int J Technol Assess Health Care. 2014; In process.
10. Henshall, C, Mardhani-Bayne, L, Frønsdal, KB, Klemp, M. Interactions between health technology assessment, coverage, and regulatory processes: Emerging issues, goals, and opportunities. Int J Technol Assess Health Care. 2011;27:253260.
11. The European Medicines Agency. Benefit-Risk Methodology Project. Doc. Ref. EMEA/108979/2009. London, 12 March 2009. http://www.ema.europa.eu/docs/en_GB/document_library/Report/2011/07/WC500109477.pdf (accessed September 19, 2013).
12. Committee for Medicinal Products for Human Use. Reflection paper on benefit-risk assessment methods in the context of the evaluation of marketing authorisation applications of medicinal products for human use. Doc. Ref. EMEA/CHMP/15404/2007. London, 19 March 2008. http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2010/01/WC500069634.pdf (accessed September 19, 2013).
13. Public Law No: 111–5. H.R. 1. American Recovery and Reinvestment Act of 2009 signed by President Barack Obama on 2/17/2009.
14. Biskupiak, JE, Dunn, JD, Holtorf, AP. Implementing CER: What will it take? J Manag Care Pharm. 2012;18 (Supp A):S19S29.

Keywords

Related content

Powered by UNSILO
Type Description Title
WORD
Supplementary materials

Kleijnen et al. supplementary material
Table 1

 Word (62 KB)
62 KB
WORD
Supplementary materials

Kleijnen et al. supplementary material
Table 2

 Word (90 KB)
90 KB

STANDARDIZED REPORTING FOR RAPID RELATIVE EFFECTIVENESS ASSESSMENTS OF PHARMACEUTICALS

  • Sarah Kleijnen (a1), Iris Pasternack (a2), Marc Van de Casteele (a3), Bernardette Rossi (a4), Agnese Cangini (a5), Rossella Di Bidino (a6), Marjetka Jelenc (a7), Payam Abrishami (a8), Ilona Autti-Rämö (a9), Hans Seyfried (a10), Ingrid Wildbacher (a10) and Wim G. Goettsch (a11)...

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.